Allogene Therapeutics

$29.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-0.51%) As of 2:12 PM UTC today

Why Robinhood?

You can buy or sell ALLO and other stocks, options, and ETFs commission-free!

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.

CEO
David D. Chang
Employees
265
Headquarters
South San Francisco, California
Founded
2017
Market Cap
4.15B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
624.36K
High Today
$30.00
Low Today
$29.30
Open Price
$29.59
Volume
69.13K
52 Week High
$55.00
52 Week Low
$22.20

ALLO Earnings

-$0.68
-$0.45
-$0.23
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 5, After Hours

You May Also Like

MGU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure